Search company, investor...
Combinati company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Acquired | Acquired

Total Raised


About Combinati

Combinati develops a digital PCR platform that offers quantification to track disease-relevant biomarkers over time.On October 4th, 2021, Combinati was acquired by Thermo Fisher Scientific, terms of the transaction were not disclosed.

Combinati Headquarters Location

3436 Rambow Drive

Palo Alto, California, 94306,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Combinati

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Combinati in 1 CB Insights research brief, most recently on Apr 23, 2020.

Expert Collections containing Combinati

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Combinati is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Health Monitoring & Diagnostics

2,418 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

Combinati Patents

Combinati has filed 12 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • DNA
  • Polymerase chain reaction
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Biotechnology, Polymerase chain reaction, DNA, Molecular biology techniques


Application Date


Grant Date



Related Topics

Molecular biology, Biotechnology, Polymerase chain reaction, DNA, Molecular biology techniques



Latest Combinati News

Thermo Fisher Scientific Unveils Q Digital PCR System for Innovation in Genetic Analysis Capabilities and Higher Research

Oct 31, 2021

Share Thermo Fisher Scientific , the world leader in serving science, introduced the Applied Biosystem QuantStudio Absolute Q-Digital PCR System, the first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes. dPCR has quickly become the standard for nucleic acid quantification in oncology, cell and gene therapy oncology development and other research applications because its absolute quantification enables higher accuracy and precision. Thermo Fisher recently acquired Combinati and its cutting-edge dPCR technology to rapidly develop and commercialize it alongside an expanding portfolio of assays. “Thermo Fisher Scientific is committed to innovation and providing the best technologies for our customers and help them accelerate innovation in areas including cancer research, rare diseases, and more. QuantStudio Absolute Q Digital PCR System is a much-needed solution in biotech and research-academia space,” said Amit Chopra, managing director, India, and South Asia, Thermo Fisher Scientific. Related Posts “The device overcomes the existing challenges of precision, operation, and turnaround time to provide an industry-best dPCR platform,” added Amit. Unlike complex, multi-instrument workflows required for traditional dPCR, the QuantStudio Absolute Q System uses microfluidic array technology and simplified workflows, designed to improve data accuracy and consistency. The device supports the pharmaceutical fraternity in innovating disease management, advancing significantly in generating consistent and accurate data. “QuantStudio Absolute Q solution is a fast and simple workflow that offers high-quality data with minimum hands-on time. It integrates all the necessary steps for dPCR—digitization, thermal cycling, and data acquisition—into a single instrument. The dPCR is already in use for longitudinal monitoring of cancer-driving mutations in liquid biopsy and precise quantification of gene inserts for cell therapy development,” said Kapil Sood, senior director, Life Sciences Solutions, Thermo Fisher Scientific

Combinati Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Combinati Rank

  • Where is Combinati's headquarters?

    Combinati's headquarters is located at 3436 Rambow Drive, Palo Alto.

  • What is Combinati's latest funding round?

    Combinati's latest funding round is Acquired.

  • How much did Combinati raise?

    Combinati raised a total of $5.83M.

  • Who are the investors of Combinati?

    Investors of Combinati include Thermo Fisher Scientific, Enlumenbio Capital and SAYA BIO.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.